Chest
Original ResearchCOPDC-Reactive Protein Levels and Survival in Patients With Moderate to Very Severe COPD
Section snippets
Study Population
This is a prospective observational study of patients from the two sites of the BODE cohort that had measured CRP levels at baseline.6, 7 Patients from the pulmonary clinics at the Hospital Universitario Ntra Sra de Candelaria, in Tenerife, Spain, and from Caritas St Elizabeth's Medical Center in Boston, MA, signed the informed consent approved by the Human Institutional Review Boards. The patients were consecutively included if they had smoked ≥20 pack-years and had a postbronchodilator FEV1
Results
The clinical and physiologic characteristics of all patients are summarized in Table 1. This predominantly male COPD population included patients with Global Initiative for Chronic Obstructive Lung Disease (GOLD)/ATS/European Respiratory Society stages II to IV. Most had a normal BMI, with 32% of them having an IC/TLC ratio <0.25. Half had an MMRC score >2 and some degree of comorbidity. At the end of the follow-up time, 25% (54 patients) had died and 7% (15 patients) were not available for
Discussion
The most important finding of this study is that a baseline serum CRP level was not significantly associated with survival status in patients with clinically stable moderate to very severe COPD. Numerous prospective studies have shown that the serum level of CRP is independently associated with future mortality. Levels of CRP are associated with cardiovascular risk of death in the general population21 as well as in patients with other conditions, such as diabetes22 and renal disease.23 Although
References (29)
- et al.
Burden and clinical features of chronic obstructive pulmonary disease (COPD)
Lancet
(2004) - et al.
Obstructive and restrictive lung disease and markers of inflammation: data from the third National Health and Nutrition Examination
Am J Med
(2003) - et al.
Validation of a combined comorbidity index
J Clin Epidemiol
(1994) - et al.
Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary
Am J Respir Crit Care Med
(2001) Systemic effects of chronic obstructive pulmonary disease
Proc Am Thorac Soc
(2005)- et al.
Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and meta-analysis
Thorax
(2004) - et al.
C-reactive protein: a critical update
J Clin Invest
(2003) - et al.
C-reactive protein levels and clinically important predictive outcomes in stable COPD patients
Eur Respir J
(2006) - et al.
C-reactive protein in patients with COPD, control smokers, and nonsmokers
Thorax
(2006) - et al.
Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease
Am J Respir Crit Care Med
(2006)
Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease
Am J Respir Crit Care Med
C-reactive protein and cardiovascular disease: weighing the evidence
Curr Atheroscler Rep
C reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease
Thorax
C-reactive protein as a predictor of prognosis in COPD
Am J Respir Crit Care Med
Cited by (129)
C-reactive protein as a biomarker of response to inhaled corticosteroids among patients with COPD
2020, Pulmonary Pharmacology and TherapeuticsElectrochemical methods for detection of biomarkers of Chronic Obstructive Pulmonary Disease in serum and saliva
2019, Biosensors and BioelectronicsCOPD-OSA Overlap Syndrome: Evolving Evidence Regarding Epidemiology, Clinical Consequences, and Management
2017, ChestCitation Excerpt :A variety of molecular pathways have been identified in this process, particularly those involving the proinflammatory transcription factor nuclear factor kappa-B and its downstream products, including tumor necrosis factor-alpha.51-55 C-reactive protein has also been identified as a measure of systemic inflammation that is commonly elevated in COPD56-59 and OSA,60,61 although in patients with OSA, concurrent obesity represents an important confounding factor.62 Systemic inflammation represents an important contributing factor to the development of cardiovascular disease, and it is notable that cardiovascular comorbidity is recognized as a common complication of both COPD and OSA.63-67
Acute Phase Reactants and the Concept of Inflammation
2016, Kelley and Firestein's Textbook of Rheumatology: Volumes 1-2, Tenth Edition
The author have no conflicts of interest to disclose.
Funding was provided partially by the Canarian Research and Health Foundation.
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/misc/reprints.html).